• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PAVmed

PAVmed completes first-in-human implantations of its intraosseous infusion system

March 17, 2022 By Sean Whooley

PAVmed PortIO

PAVmed (Nasdaq:PAVM) has successfully completed the first human implants of its PortIO intraosseous infusion system, the company said today. New York-based PAVmed designed its PortIO system with an implantable intraosseous vascular access device and insertion kit. Instead of a catheter located in a vein, the system has a short extension from the device inserted by […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Vascular Tagged With: PAVmed

Pavmed lands $10m from oversubscribed rights offering

June 8, 2018 By Sarah Faulkner

Pavmed

Pavmed (NSDQ:PAVM) said today that it expects to reel in $10.4 million in gross proceeds from an oversubscribed rights offering that expired this week. The New York-based company received subscriptions exceeding the number of rights available under the offering, Pavmed said, adding that it anticipates the offering will close on June 12. According to the terms […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Otolaryngology Ear, Nose & Throat, Wall Street Beat Tagged With: PAVmed

Pavmed registers for $20m rights offering

May 8, 2018 By Sarah Faulkner

Pavmed

Pavmed (NSDQ:PAVM) said today that it filed a preliminary prospectus with the SEC for an offering of the rights to buy a new unit in exchange for each share of outstanding common stock. The medical device company plans to offer the rights to purchase up to 9 million units at $2.25 apiece on May 21, valuing […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: PAVmed

Medtech stories we missed this week: April 27, 2018

April 27, 2018 By Danielle Kirsh

canyon at sunset

From DuPuy Synthes’s spinal implant launch to Lumendi’s FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. DePuy Synthes launches spinal implants DePuy Synthes announced in an April 26 press release that it has launched its Proti 360º integrated titanium family of interbody devices that are designed to […]

Filed Under: Featured, Food & Drug Administration (FDA), Hematology, Hospital Care, Orthopedics, Regulatory/Compliance Tagged With: abbott, apolloendosurgery, Cerus Corp., DePuy Synthes, lumendi, PAVmed, reshapelifesciences, sanquin

Pavmed closes warrant exchange offer

April 5, 2018 By Sarah Faulkner

Pavmed

Pavmed Inc. (NSDQ:PAVM) said today that it closed its offer to exchange two Series W warrants for a single Z warrant. Approximately 10,151,682 Series W warrants were tendered and not withdrawn, which represents 96.4% of outstanding Series W warrants, the New York-based company said. Pavmed plans to accept all 10.2 million of the Series W warrants and, […]

Filed Under: Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: PAVmed

Pavmed reports prelim results of warrant exchange offer

April 4, 2018 By Sarah Faulkner

Pavmed

Pavmed Inc. (NSDQ:PAVM) today reported the preliminary results of its offer to exchange two Series W warrants for a single Z warrant. Approximately 10,151,682 Series W warrants were tendered and not withdrawn, which represents 96.4% of outstanding Series W warrants, the New York-based company said. Pavmed plans to accept all 10.2 million of the Series W […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: PAVmed

Pavmed extends Series W warrant exchange offer through April

March 19, 2018 By Fink Densford

Pavmed

Pavmed Inc. (NSDQ:PAVM) said last week it plans to extend its previously announced offering to exchange two Series W warrants for a single Series Z warrant. The offering from the New York-based company is now extended through to April 2, having previously been set to close today at midnight, according to a press release. Pavmed offered […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: PAVmed

Pavmed floats exchange offer for discounted Series W shares

February 12, 2018 By Sarah Faulkner

Pavmed

Pavmed Inc. (NSDQ:PAVM) today offered to trade a pair of its just-sold Series W warrants for a single Series Z unit worth $5.oo apiece. The New York-based company previously offered the opportunity for investors to exercise the Series W warrants at a discounted price of $2.00 per share. As of Feb. 8, Pavmed said 34,345 Series […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: PAVmed

Pavmed shares climb after Q3 EPS beat

November 15, 2017 By Sarah Faulkner

Pavmed

Shares in Pavmed Inc. (NSDQ:PAVM) rose today after the medical device maker beat expectations on Wall Street with its third quarter results. The N.Y.-based company posted a net loss of -$5.37 million, or -40¢ per share, for the 3 months ended Sept. 30, for bottom-line loss of -178.5% compared with the same period last year. Adjusted […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: PAVmed

Pavmed to drop 510(k), pursue de novo pathway for PortIO infusion system

October 4, 2017 By Sarah Faulkner

Pavmed

Pavmed Inc. (NSDQ:PAVM) plans to drop the 510(k) application for its PortIO intraosseous infusion system and instead pursue a de novo pathway for its device, according to a document the company filed with the SEC yesterday. The move is based on a recommendation from the FDA, the company said. The company’s 510(k) relied upon substantial equivalence […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: PAVmed

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS